uniQure (QURE) Free Cash Flow (2016 - 2026)
uniQure (QURE) posted quarterly Free Cash Flow of -$29.0 million for Q2 2026, up 27.66% year-over-year from -$22.8 million in Q2 2025, and up 24.32% quarter-over-quarter from -$38.4 million in Q1 2026.
Powered by 
Analysis
uniQure (QURE) Free Cash Flow (2016 - 2026) Analysis & Trends
uniQure's Free Cash Flow history runs 11 years deep, the most recent figure standing at -$29.0 million for Q2 2026.
- In Q2 2026, Free Cash Flow rose 27.66% year-over-year to -$29.0 million; the TTM figure through Jun 2026 stood at -$161.5 million (up 7.34% YoY), while the FY2025 annual figure was -$178.4 million, up 4.13% from the prior year.
- Free Cash Flow for Q2 2026 stood at -$29.0 million, up from -$38.4 million in the prior quarter.
- The five-year high for Free Cash Flow was $37.2 million in Q3 2023, with the low at -$80.6 million in Q1 2023.
- The 5-year median for Free Cash Flow is -$42.2 million (2025), against an average of -$41.5 million.
- The sharpest annual moves came in 2023 and 2024: Free Cash Flow soared 170.24% in 2023, then plunged 199.37% in 2024.
- uniQure's Free Cash Flow stood at -$59.7 million in 2022, then rose by 13.67% to -$51.6 million in 2023, then fell by 2.53% to -$52.9 million in 2024, then slumped by 46.9% to -$77.7 million in 2025, then surged by 62.61% to -$29.0 million in 2026.
- Business Quant data shows QURE's Free Cash Flow at -$29.0 million in Q2 2026, -$38.4 million in Q1 2026, and -$77.7 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -95.09 Mn |
| 10 | uniQure | 2.95 Bn | 2.95 Bn | 5.49 Mn | -29.05 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -29.05 Mn |
| Mar 31, 2026 | -38.38 Mn |
| Dec 31, 2025 | -77.69 Mn |
| Sep 30, 2025 | -16.33 Mn |
| Jun 30, 2025 | -40.16 Mn |
| Mar 31, 2025 | -44.23 Mn |
| Dec 31, 2024 | -52.88 Mn |
| Sep 30, 2024 | -36.98 Mn |
| Jun 30, 2024 | -33.32 Mn |
| Mar 31, 2024 | -62.92 Mn |
| Dec 31, 2023 | -51.58 Mn |
| Sep 30, 2023 | 37.21 Mn |
| Jun 30, 2023 | -58.07 Mn |
| Mar 31, 2023 | -80.64 Mn |
| Dec 31, 2022 | -59.75 Mn |
| Sep 30, 2022 | -52.98 Mn |
| Jun 30, 2022 | -20.26 Mn |
| Mar 31, 2022 | -29.77 Mn |
| Dec 31, 2021 | -50.64 Mn |
| Sep 30, 2021 | -47.85 Mn |